Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3 ##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3 ##STR00001##

A fluorinated imide salt compound of the present invention is a compound represented by General Formula (1). In General Formula (1), m represents 1 or 2, n represents an integer from 1 to 4, α represents 1 or 2, and X.sup.α+ represents an α-valent metal ion, a primary ammonium ion, a secondary ammonium ion, a tertiary ammonium ion, a quaternary ammonium ion, or NH.sub.4.sup.+.

##STR00001##

A fluorinated imide salt compound of the present invention is a compound represented by General Formula (1). In General Formula (1), m represents 1 or 2, n represents an integer from 1 to 4, α represents 1 or 2, and X.sup.α+ represents an α-valent metal ion, a primary ammonium ion, a secondary ammonium ion, a tertiary ammonium ion, a quaternary ammonium ion, or NH.sub.4.sup.+.

##STR00001##

According to the present invention, there is provided a method of producing a salt, including reacting M.sup.+X.sup.− with YH to generate XH and M.sup.+Y.sup.− and subsequently removing the generated XH to obtain the M.sup.+Y.sup.−.

In the method of producing a salt, M.sup.+X.sup.− is a salt of a cation represented by M.sup.+ and an anion represented by X.sup.−, M.sup.+Y.sup.− is a salt of the cation represented by M.sup.+ and an anion represented by Y.sup.−, XH is a conjugate acid of X.sup.−, YH is a conjugate acid of Y.sup.−, M.sup.+Y.sup.− is a compound that generates an acid upon irradiation with an active ray or a radioactive ray, a pKa of XH is larger than a pKa of YH, and a ClogP value of XH is larger than 2.

According to the present invention, there is provided a method of producing a salt, including reacting M.sup.+X.sup.− with YH to generate XH and M.sup.+Y.sup.− and subsequently removing the generated XH to obtain the M.sup.+Y.sup.−.

In the method of producing a salt, M.sup.+X.sup.− is a salt of a cation represented by M.sup.+ and an anion represented by X.sup.−, M.sup.+Y.sup.− is a salt of the cation represented by M.sup.+ and an anion represented by Y.sup.−, XH is a conjugate acid of X.sup.−, YH is a conjugate acid of Y.sup.−, M.sup.+Y.sup.− is a compound that generates an acid upon irradiation with an active ray or a radioactive ray, a pKa of XH is larger than a pKa of YH, and a ClogP value of XH is larger than 2.

Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.

Disclosed are compounds of Formula 1, all stereoisomers, N-oxides, and salts thereof,

##STR00001##

wherein G is CONR.sup.5R.sup.6 or selected from

##STR00002## and R.sup.1 through R.sup.18, R.sup.f and G are as defined in the Disclosure.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.